Platelet activation and aggregation pathway

The platelet activation and aggregation pathway is a complex biological system essential for primary hemostasis and the primary driver of arterial thrombosis [1]. It involves a coordinated sequence of events where platelets adhere to damaged vascular endothelium, undergo activation through various surface receptors, and ultimately aggregate to form a stable plug [2]. Key molecular components include the Glycoprotein Ib-IX-V complex for initial adhesion, G protein-coupled receptors like P2Y12 and PAR-1 for activation, and the integrin alpha-IIb/beta-3 (GPIIb/IIIa) for final aggregation via fibrinogen bridging [1, 3]. Dysregulation of this machinery leads to pathological conditions such as myocardial infarction and ischemic stroke [2]. Pharmacological intervention targets specific nodes within this pathway, including the inhibition of cyclooxygenase-1 (COX-1) by aspirin and the antagonism of P2Y12 receptors by thienopyridines [4]. While these antiplatelet therapies are critical for preventing cardiovascular events, they are associated with significant safety concerns, most notably an increased risk of major bleeding and gastrointestinal complications [4]. Sources: [1] StatPearls: Platelet Aggregation (https://www.ncbi.nlm.nih.gov/books/NBK553137/) [2] NIH/NCBI: Platelet Activation and Aggregation (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035177/) [3] PubMed: Mechanisms of Platelet Activation (https://pubmed.ncbi.nlm.nih.gov/28258100/) [4] Merck Manual: Antiplatelet Drugs (https://www.merckmanuals.com/professional/hematology-and-oncology/hemostasis/antiplatelet-drugs)

Other names

Platelet activation/aggregation machineryPlatelet activation pathwayPlatelet aggregation pathwayPrimary hemostasis machineryThrombotic cascade

Drugs targeting this machinery act by inhibiting cyclooxygenase-1 (COX-1) to prevent thromboxane A2 synthesis, antagonizing P2Y12 purinergic receptors to block ADP-mediated activation, inhibiting the Glycoprotein IIb/IIIa (integrin alpha-IIb/beta-3) receptor to prevent fibrinogen-mediated aggregation, or antagonizing Protease-activated receptor 1 (PAR-1) to block thrombin-induced signaling.